Status:
COMPLETED
Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers
Lead Sponsor:
Montefiore Medical Center
Collaborating Sponsors:
Sanofi
GlaxoSmithKline
Conditions:
Ovarian Neoplasms
Uterine Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The primary aim of this study is: * To determine the overall clinical response rate of weekly Topotecan and Taxotere in women with recurrent ovarian, primary peritoneal, endometrial and uterine cance...
Detailed Description
Endometrial carcinoma is the most common gynecologic cancer, accounting for 6,500 deaths in 2002 in the United States. There has been a 128% increase in endometrial cancer deaths over the past decade ...
Eligibility Criteria
Inclusion
- Histologically documented recurrent endometrial adenocarcinoma, papillary serous (UPSC), or mixed mullerian tumor (MMT) for which a cure or substantial palliation is unlikely using surgery and/or radiotherapy. Patients must have measurable disease or disease felt to be reproducibly measurable on CT scan, chest x-ray and/or tumor marker elevations .
- Recurrent ovarian or primary peritoneal cancers as defined as either:
- Measurable disease either by physical examination or by imaging or
- Non-measurable evidence of disease such as any or all of the following standard Rustin criteria:
- Peritoneal implants \<2 cm
- Abnormal densities on computerized tomography (CT) scan and/or loculated fluid collections
- Elevated CA-125 (\>100 U/mL on 2 measurements at least 1 week apart) and disease- related symptoms.
- Patients with the following histologic ovarian or uterine epithelial cell types are eligible:
- Serous adenocarcinoma
- Endometrioid adenocarcinoma
- Mucinous adenocarcinoma
- Undifferentiated carcinoma
- Clear cell adenocarcinoma
- Mixed epithelial carcinoma
- Transitional cell
- Malignant Brenner's tumor
- Adenocarcinoma NOS
- Age ≥ 18 years.
- ECOG performance status of ≤ 2.
- Peripheral neuropathy must be ≤ grade 1
- Previously treated patients must have received no antineoplastic treatment for at least 4 weeks. Patients will not have received more than two previous chemotherapy regimens.
- In patients previously irradiated, the recurrent disease should be outside of the radiotherapy portal or have developed disease progression within the radiated field.
- No concurrent chemotherapy, radiotherapy, immunotherapy, or hormone therapy.
- Hepatic:
- Total bilirubin ≤ ULN
- AST and ALT and alkaline phosphatase must be within the range allowing for eligibility.
- Patients must be alert, oriented, and have signed an informed consent in accordance with institutional policies and be aware of the investigational nature of the study.
- Women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter
Exclusion
- Patient has impairment of hepatic, renal or hematologic function as defined by the following baseline laboratory values:
- Serum creatinine clearance ≤ 50 ml/min
- Platelets \<100,000/mm3
- Absolute neutrophil count (ANC) \<1500/mm3
- Hemoglobin \<8.0 g/dl (the patient may be transfused prior to study entry)
- History of chronic or active hepatitis
- Patient has severe or uncontrolled medical disease (eg. uncontrolled diabetes, unstable angina, myocardial infarction within 6 months, congestive heart failure, etc.)
- Patients with dementia or altered mental status that would prohibit the giving and understanding of informed consent at time of study entry.
- Patients with a history of severe hypersensitivity to Taxotere®, Topotecan®, or other drugs formulated with polysorbate 80.
- Women who are pregnant or breast-feeding
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
March 1 2007
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT00231855
Start Date
November 1 2004
End Date
March 1 2007
Last Update
April 24 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Montefiore Medical Center
The Bronx, New York, United States, 10461